USFDA grants priority review to Merck’s NDA for HIF-2α inhibitor Belzutifan

Belzutifan is a novel investigational therapy for the potential treatment of patients suffering from von Hippel-Lindau (VHL) disease-associated renal cell carcinoma. Credit: Robina Weermeijer/Unsplash.